Interferon a and T-cell responses in chronic myeloid leukemia

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Leukemia & Lymphoma

• Publication date

  2005-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10428190400012029
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.

  2004cited by this paper
• Monocyte Activation by Circulating Fibronectin Fragments in HIV-1-Infected Patients1

  2004cited by this paper
• Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo.

  2004cited by this paper
• Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase.

  2004cited by this paper
• Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis.

  2004cited by this paper
• Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens1

  2004cited by this paper
• Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.

  2004cited by this paper
• The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha.

  2004cited by this paper
• Cancer Immunotherapy: A Treatment for the Masses

  2004cited by this paper
• IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment.

  2004cited by this paper
• Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

  2004cited by this paper
• [Interferon : antiviral mechanisms and viral escape].

  2003cited by this paper
• IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities.

  2003cited by this paper
• Interferons and Apoptosis

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Competition Between Two MHC Binding Registers in a Single Peptide Processed from Myelin Basic Protein Influences Tolerance and Susceptibility to Autoimmunity

  2003cited by this paper
• The human interferon system: characterization and classification after discovery of novel members.

  2003cited by this paper
• Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.

  2003influential reference
• Disparity for a newly identified minor histocompatibility antigen, HA‐8, correlates with acute graft‐versus‐host disease after haematopoietic stem cell transplantation from an HLA‐identical sibling

  2003cited by this paper
• Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

  2003cited by this paper
• Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis

  2003cited by this paper
• Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

  2003cited by this paper
• Type I interferons produced by dendritic cells promote their phenotypic and functional activation.

  2002cited by this paper
• Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.

  2002cited by this paper
• CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

  2002cited by this paper
• Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.

  2002cited by this paper
• Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression.

  2002cited by this paper
• Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa.

  2002cited by this paper
• Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

  2001influential reference
• Negative Selection during the Peripheral Immune Response to Antigen

  2001cited by this paper
• HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.

  2001cited by this paper
• Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.

  2001cited by this paper
• Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.

  2000cited by this paper
• Type 1 IFN Maintains the Survival of Anergic CD4+ T Cells1

  2000cited by this paper
• Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

  2000cited by this paper
• Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.

  2000cited by this paper
• Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.

  2000cited by this paper
• Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

  2000influential reference
• HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.

  2000cited by this paper
• IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs.

  2000cited by this paper
• IFN-α-Expressing Tumor Cells Enhance Generation and Promote Survival of Tumor-Specific CTLs

  2000cited by this paper
• Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.

  2000cited by this paper
• Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

  2000cited by this paper
• De novo synthesis of proteinase 3 by cytokine primed circulating human polymorphonuclear neutrophils and mononuclear cells.

  2000cited by this paper
• Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.

  2000cited by this paper
• Proteinase 3 mRNA expression is induced in monocytes but not in neutrophils of patients with cystic fibrosis

  1999cited by this paper
• Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells.

  1999cited by this paper
• An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

  1999cited by this paper
• Tetrameric HLA class I–minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease

  1999cited by this paper
• Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.

  1999cited by this paper
• Type I Interferons Keep Activated T Cells Alive

  1999cited by this paper
• Interferon- Activates Multiple STAT Proteins and Upregulates Proliferation-Associated IL-2R, c-myc, and pim-1 Genes in Human T Cells

  1999cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia.

  1998cited by this paper
• Induction and Exhaustion of Lymphocytic Choriomeningitis Virus–specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I–Peptide Complexes

  1998cited by this paper
• Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells

  1998cited by this paper
• Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha.

  1998cited by this paper
• Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.

  1998cited by this paper
• Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

  1998cited by this paper
• Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

  1998cited by this paper
• A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

  1998cited by this paper
• Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia.

  1998cited by this paper
• Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

  1998cited by this paper
• The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.

  1998cited by this paper
• Type I IFNs enhance the terminal differentiation of dendritic cells.

  1998cited by this paper
• Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukaemia

  1997cited by this paper
• Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.

  1997cited by this paper
• Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms.

  1997cited by this paper
• Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation.

  1996cited by this paper
• Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation.

  1996cited by this paper
• Cellular interactions in thymocyte development.

  1996cited by this paper
• Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.

  1996cited by this paper
• Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.

  1996cited by this paper
• Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis.

  1996cited by this paper
• c-ANCA as a marker of Wegener's disease.

  1996cited by this paper
• Specific human cellular immunity to bcr-abl oncogene-derived peptides.

  1996cited by this paper
• c-ANCA as a marker of Wegener's disease.

  1996cited by this paper
• IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2.

  1996cited by this paper
• Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

  1995cited by this paper
• A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.

  1995cited by this paper
• Identification of a graft versus host disease-associated human minor histocompatibility antigen.

  1995cited by this paper
• Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.

  1994cited by this paper
• T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG)

  1994cited by this paper
• In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease.

  1994cited by this paper
• Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis.

  1994cited by this paper
• Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

  1994cited by this paper
• Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.

  1993cited by this paper
• Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

  1993cited by this paper
• Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

  1993cited by this paper
• Loss of HLA class‐I alleles, heavy chains and β2‐microglobulin in colorectal cancer

  1992influential reference
• Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes.

  1992cited by this paper
• Expression of the Wilms' tumor gene (WT1) in human leukemias.

  1992cited by this paper
• Proteinase 3, the target antigen of anticytoplasmic antibodies circulating in Wegener's granulomatosis. Immunolocalization in normal and pathologic tissues.

  1991cited by this paper
• An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes.

  1990cited by this paper
• Graft-versus-leukemia reactions after bone marrow transplantation.

  1990cited by this paper
• Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy.

  1989cited by this paper
• Staging and prognosis in chronic myelogenous leukemia.

  1988cited by this paper
• Effect of Recombinant α-Interferon on the Expression of the bcr-abl Fusion Gene in Human Chronic Myelogenous Human Leukemia Cell Lines

  1987cited by this paper

• Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

  2023cites this paper
• Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia

  2023cites this paper
• Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future

  2021cites this paper
• A quantitative study on the role of TKI combined with Wnt/β-catenin signaling and IFN-α in the treatment of CML through deterministic and stochastic approaches

  2019cites this paper
• Optimization of Combined Leukemia Therapy by Finite-Dimensional Optimal Control Modeling

  2017cites this paper
• The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms

  2017cites this paper
• CYR61 suppresses growth of human malignant melanoma.

  2016cites this paper
• The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia

  2015cites this paper
• Stability and Controllability Issues in Mathematical Modeling of the Intensive Treatment of Leukemia

  2015cites this paper
• Chapter 66 – Immunotherapy

  2014cites this paper
• Regulation of hematopoietic and leukemic stem cells by the immune system

  2014cites this paper
• Whole Blood Transcriptional Profi ling Reveals Signifi cant Downregulation of HLA Class I and II Genes in Essential Thrombocythemia, Polycythemia Vera and Myelofi brosis

  2013cites this paper
• malignancies The renaissance of interferon therapy for the treatment of myeloid

  2013cites this paper
• Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis

  2013cites this paper
• Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia.

  2012cites this paper
• A mathematical model with time-varying delays in the combined treatment of chronic myeloid leukemia

  2012cites this paper
• Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia.

  2012cites this paper
• From Concept to the Clinics: Development of Cancer Therapeutics

  2011cites this paper
• The renaissance of interferon therapy for the treatment of myeloid malignancies.

  2011cites this paper
• Treatment for production of interferon-alpha (ifn-α) and interferon-gamma (ifn-γ) from the same purified suspension of leukocytes

  2011cites this paper
• Chronische myeloische Leukämie

  2011cites this paper
• From Concept to the Clinics: Development of Novel Large Molecule Cancer Therapeutics

  2010cites this paper
• Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.

  2010cites this paper
• Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?

  2009cites this paper
• Peptide vaccines for patients with acute myeloid leukemia

  2009cites this paper
• BCL-2 family function in antiestrogen-resistant breast cancer cells

  2009cites this paper
• CHAPTER 72 – Immunotherapy

  2007cites this paper
• Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients.

  2007cites this paper
• The role of interferon-alpha in the treatment of chronic myeloid leukemia.

  2007cites this paper
• Functional Annotation of IFN-α-Stimulated Gene Expression Profiles from Sensitive and Resistant Renal Cell Carcinoma Cell Lines

  2006cites this paper
• Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment.

  2006cites this paper
• Immune therapy of chronic myelogenous leukemia.

  2005cites this paper